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BACKGROUND: The purpose of this study was to test a novel, dual tumour vascular endothelial cell (VEC)- and tumour cell-targeting
factor VII-targeted Sn(IV) chlorin e6 photodynamic therapy (fVII-tPDT) by targeting a receptor tissue factor (TF) as an alternative
treatment for chemoresistant breast cancer using a multidrug resistant (MDR) breast cancer line MCF-7/MDR.
METHODS: The TF expression by the MCF-7/MDR breast cancer cells and tumour VECs in MCF-7/MDR tumours from mice was
determined separately by flow cytometry and immunohistochemistry using anti-human or anti-murine TF antibodies. The efficacy of
fVII-tPDT was tested in vitro and in vivo and was compared with non-targeted PDT for treatment of chemoresistant breast cancer.
The in vitro efficacy was determined by a non-clonogenic assay using crystal violet staining for monolayers, and apoptosis and necrosis
were assayed to elucidate the underlying mechanisms. The in vivo efficacy of fVII-tPDT was determined in a nude mouse model of
subcutaneous MCF-7/MDR tumour xenograft by measuring tumour volume.
RESULTS: To our knowledge, this is the first presentation showing that TF was expressed on tumour VECs in chemoresistant breast
tumours from mice. The in vitro efficacy of fVII-tPDT was 12-fold stronger than that of ntPDT for MCF-7/MDR cancer cells, and the
mechanism of action involved induction of apoptosis and necrosis. Moreover, fVII-tPDT was effective and safe for the treatment of
chemoresistant breast tumours in the nude mouse model.
CONCLUSIONS: We conclude that fVII-tPDT is effective and safe for the treatment of chemoresistant breast cancer, presumably by
simultaneously targeting both the tumour neovasculature and chemoresistant cancer cells. Thus, this dual-targeting fVII-tPDT could
also have therapeutic potential for the treatment of other chemoresistant cancers.
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Chemotherapy resistance is a major problem in the management
of patients with breast cancer. To alternatively and effectively treat
chemoresistant breast tumours, we propose to simultaneously
target tumour neovasculature and tumour cells using a ligand-
targeted photodynamic therapy (PDT) that we recently developed
for treatment of breast cancer (Hu et al, 2010a,b). Like
chemosensitive cancer, chemoresistant cancer requires tumour
blood vessels to provide nutrients and oxygen (Bairey et al, 2000).
It is believed that targeting tumour neovasculature is a better
strategy for cancer therapy than targeting cancer cells (Alessi et al,
2004), and we believe that targeting both the tumour neovascu-
lature and tumour cells can achieve a better effect than targeting
either type of these cells alone (Hu et al, 1999, 2010a,b; Hu and
Garen, 2000, 2001).
Photodynamic therapy is a treatment involving three compo-
nents: a photoactivatable photosensitiser (PS), laser light and
tissue oxygen. The current applications of PDT involve intrave-
nous injection of PS, followed by irradiation of the diseased lesion
with a laser light. The PS can absorb light with a 600–700nm
wavelength. In turn, it converts oxygen to cytotoxic radicals and
singlet-oxygen ions. These toxic molecules in the cells then cause
cellular necrosis and/or apoptosis. Photodynamic therapy has
clinical indications in the treatment of localised cancers and has
therapeutic potential for local recurrence of chemoresistant
tumours (Capella and Capella, 2003; Merlin et al, 2003). However,
a serious limitation of the conventional PDT procedure using non-
targeted PS (ntPDT) is the toxicity that results from internalisation
of the PS by normal cells. To overcome the poor selectivity of PS,
antibodies and ligands for receptors on tumour cells were tested to
target PS into tumour cells (Mayo et al, 2003; Sharman et al, 2004).
However, there are no published studies to date regarding
neovascular- and cancer cell-targeting PDT for chemoresistant
breast cancer.
The objective of this study was to target cancer cells and tumour
neovasculature for alternative treatment of chemoresistant breast
cancer using a factor VII (fVII)-targeted PDT that we recently
developed (Hu et al, 2010a,b). It is known that fVII is a natural
ligand for receptor tissue factor (TF), with high specificity and
affinity (dissociation constant up to 1pM) (Waxman et al, 1992).
The TF expression is detected on endothelial cells of pathological
capillary blood vessels associated with solid tumours (Contrino
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set al, 1996; Shoji et al, 1998; Hu et al, 1999; Hu and Garen, 2001;
Tang et al, 2007), wet macular degeneration (wMD) (Bora et al,
2003; Tezel et al, 2007) and endometriosis (Krikun et al, 2010);
however, TF is not expressed on endothelial cells of normal blood
vessels (Drake et al, 1989; Flossel et al, 1994; Contrino et al, 1996;
Hu et al, 1999; Hu and Garen, 2001). In addition, TF is
overexpressed in cancer cells and cancer stem cells in solid
tumours (Callander et al, 1992; Shoji et al, 1998; Hu et al, 1999; Hu
and Garen, 2000, 2001; Fernandez and Rickles, 2002; Forster et al,
2006; Milsom et al, 2007) and leukaemia (Andoh et al, 1987; Bauer
et al, 1989; Hair et al, 1996). Therefore, TF can be regarded as a
common but specific therapeutic target on angiogenic tumour
vascular endothelial cells (VECs) and tumour cells based on its
selective expression. Using a well-established multidrug resistant
(MDR) breast cancer MCF-7/MDR line (Kiss et al, 1994) as a model
resistant cancer line, we report for the first time that TF expression
is observed on tumour VECs in chemoresistant human breast
tumour xenograft in mice and then report the efficacy and safety of
fVII-targeted SnCe6 PDT (Hu et al, 2010a) for effective treatment
of chemoresistant breast cancer in vitro and in vivo.
MATERIALS AND METHODS
Cell lines
Chinese hamster ovary cells (CHO-K1, ATCC) were grown in F-12
medium. The human breast cancer parental chemosensitive MCF-7
and chemoresistant MCF-7/MDR (kindly provided by Dr Zping
Lin and Dr Alan Clayton Sartorelli at Yale University) were grown
in DMEM supplemented with 10% FBS and 1:100 penicillin/
streptomycin (Sigma, St Louis, MO, USA) at 371C and 5% CO2.
Western blotting for MDR (gp170) expression by MCF-7/MDR
Human breast cancer MCF-7 and MCF-7/MDR cells were grown in
growth medium in six-well plates. When the cells reached B90%
confluence, the cells were washed once with PBS and cell membrane
proteins were extracted with M-PER mammalian membrane
extraction solution (Pierce, Rockford, IL, USA) and subjected to
SDS–PAGE and western blotting analysis. For the western analysis,
the nitrocellulose membrane (NC) was first probed with 1mgml
–1
mouse anti-gp170 (clone C219 from Covance, Princeton, NJ, USA),
followed by 0.01mgml
–1anti-mouse IgG HRP (Vector Laboratories,
Burlingame, CA, USA) and ECL reagents (GE Healthcare, Piscataway,
NJ, USA). After exposure to gp170, the NC membrane was stripped
using stripping buffer (Pierce), followed by incubation with 1mgml
–1
anti-GAPDH monoclonal antibody (Research Diagnostics Inc.,
Concord, MA, USA), 0.01mgml
–1anti-mouse IgG HRP and ECL to
ensure equal loading of protein samples for the western analysis.
Flow cytometry for TF expression using monoclonal anti-HTF
Flow cytometry was performed using 20mgml
–1 goat anti-HTF
(American Diagnostica, Stamford, CT, USA), followed by 20mgml
–1
secondary anti-goat IgG Fc FITC (Vector Laboratories) similar to
previously described methods (Hu et al, 1999, 2010a; Hu and Garen,
2000, 2001).
Production and purification of the mfVII protein
The plasmid containing mfVII cDNA was constructed, as
described in our recent papers (Hu et al, 2010a,b). Briefly, the
mouse factor VII cDNA containing a K341A mutation was derived
from a previously constructed Icon plasmid vector pcDNA3.1(þ)/
mfVII(K341A)/hIgG1 Fc (Hu et al, 1999; Hu and Garen, 2000,
2001). The new mfVII cDNA was composed of the coding sequence
of mfVII, a BamHI site, and a sequence encoding the first 15
amino-acid residues of ribonuclease S-peptide with a D14N
mutation (Kim and Raines, 1993) followed by eight histidines
(His tag) (mfVII(K341A)/Sp(D14N)/His, abbreviated as fVII,
unless specified). The S-peptide and His tag were designed for
detection and purification of fVII proteins. CHO-K1 cells were
stably transfected with the plasmid vector and grown in serum-free
medium SHM4CHO (Thermo Scientific, Basingstoke, UK) supple-
mented with a final concentration of 1mgml
–1vitamin K1 (Sigma)
similar to previously described methods (Hu et al, 1999; Hu and
Garen, 2000, 2001). The fVII protein as a secreted protein was
purified from the collected SFM from the CHO-K1 cells using
Ni-NTA affinity resins for His-tagged proteins (Qiagen, Valencia,
CA, USA), as described (Hu et al, 2010a,b).
Conjugation of fVII protein to SnCe6
The following conjugation procedure has been used to conjugate
COOH group-containing photosensitisers (verteporfin and SnCe6)
to fVII protein using crosslinker EDC (N’-3-dimethylaminopropyl-
N-ethylcarbodiimide hydrochloride; Sigma), as described in detail
by Hu et al (2010a,b). Briefly, Sn(IV) Ce6 dye (MW 850.21)
(Frontier Scientific, Logan, UT, USA) was first activated by EDC,
and then fVII protein was added to the activated dye for
conjugation. The fVII-conjugated SnCe6 was separated from
unconjugated SnCe6 using Sephadex G50 spin columns (Roche,
Indianapolis, IN, USA). The collected fVII-SnCe6 conjugate was
characterised by spectral scanning (200–800nm) and by reading
absorbance at 635nm (A635nm) using a spectrophotometer
(Beckman, Brea, CA, USA). The protein concentration was
determined by Protein Assay Reagent (Bio-Rad, Hercules, CA,
USA), and the concentration of SnCe6 was calculated based on
A635nm using a SnCe6 standard curve. Based on their molar
concentrations (mM), the molar ratio of dye to protein was
(4.21±0.95):1 (mean±s.d., n¼11), as the same preparations
of the fVII-SnCe6 conjugates as reported in our recent article
(Hu et al, 2010a) were used in this study.
In vitro PDT in tissue culture plates
The in vitro PDT tests were done in 96-well plates containing
1 10
4 cells in 100ml growth medium per well, as described in the
supplementary information in Hu et al (2010a). Briefly, fVII-tPDT
or ntPDT was carried out by incubating the cells with different
concentrations of fVII-SnCe6 conjugate or unconjugated SnCe6 at
371C for 90min, followed by washing the cells once and adding the
growth medium. The cells were irradiated with a 635nm fibre-
coupled diode laser (BWF2-635-0.1-100-0.22; B&W Tek Inc.,
Newark, DE, USA) for various time durations at 100mWcm
–2.
Controls included an untreated cell control and a maximal killing
control. All of the controls included the same number of cancer
cells. In the maximal killing control wells, cells were lysed by
addition of 1/10 volume of 9% Triton X-100 45min before crystal
violet staining. After treatment with PDT, the cells were incubated
at 371C and 5% CO2 until the untreated cells in the control wells
reached 95% confluence and then the cells in the experimental and
control wells were fixed and stained for the crystal violet staining
assay described below.
Crystal violet staining to determine the in vitro efficacy of
SnCe6 PDT
Non-clonogenic crystal violet staining for monolayer cell mem-
brane loss was performed as previously described (Mickuviene
et al, 2004) with a minor modification for the more convenient
reading of absorbance at 595nm (A595nm) (Hu et al, 2010a,b).
The in vitro efficacy was presented as the percentage of surviving
cells based on A595nm readings by the crystal violet staining
assay. Percent of surviving cells (%)¼(A595nm of PDT-treated
cells average A595nm of maximal killing controls)/(average
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killing controls) 100%.
Assessing apoptosis and necrosis as a mechanism of action
of SnCe6 PDT
MCF-7/MDR breast cancer cells were treated in 96-well plates with
fVII-tPDT or ntPDT (2mM,7 2 J c m
–2) as described above. At
various time points after PDT treatment, the plates were separately
assayed for necrosis (cytotoxicity) using the fluorescence-based
Cytotox-ONE Homogeneous Membrane Integrity Assay kit
(Promega) and apoptosis using the Apo-ONE Homogeneous
Caspase-3/7 Assay kit (Promega, Madison, WI, USA). This was
performed by measuring fluorescence on a fluorescence microplate
reader (SpectraMax Gemini XS, Molecular Devices, Sunnyvale, CA,
USA) following the manufacturer’s instructions. Percent of
cytotoxicity or apoptosis¼(fluorescence in treated cells–fluores-
cence in untreated cells)/(fluorescence in maximal killing control–
fluorescence in untreated cells) 100%.
To visualise the early events of apoptosis and necrosis, 2 10
4
MCF-7/MDR cancer cells per well were seeded in 96-well plate
overnight. Next day, the cells were separately treated by fVII-tPDT
using fVII-SnCe6 conjugate and ntPDT using unconjugated SnCe6
(2mM SnCe6 and 36Jcm
–2), or were not treated as untreated
control. Immediately after the treatment the cancer cells were
stained with 1:20 diluted Annexin V-FITC for early detection of
apoptotic cells and then stained with 1mgml
–1 propidium iodide
(PI) for necrotic cells using ApoDETECT ANNEXIN V-FITC KIT
(Invitrogen, Carlsbad, CA, USA). After staining, the cells were
observed and photographed under fluorescence microscope.
In vivo fVII-tPDT treatment of human chemoresistant
breast cancer MCF-7/MDR tumour xenografts in a nude
mouse model
The animal study protocol was reviewed and approved by the
Institutional Animal Care and Use Committee of Yale University.
Human chemoresistant tumour xenografts were generated by sub-
cutaneous injection of 150ml equal volume mixture of PBS and
Matrigel (BD Biosciences, Bedford, MA, USA) containing 3 10
6
MCF-7/MDR cancer cells per mouse in 4- to 6-week-old female
athymic nude mice (NCr nude homozygous, Taconic Farms,
Germantown, NY, USA) s.c. implanted with 17 b-estradiol pellet
(60 day release, 1.7 mg per pellet) (Innovative Research of America,
Sarasota, FL, USA), as described (Hu et al, 1999, 2010a,b; Hu and
Garen, 2000, 2001). After the tumours reached 100–200mm
3 in size,
fVII-SnCe6 conjugate was intravenously (i.v.) injected into mouse tail
veins at a final concentration of 2mM SnCe6 using an estimate of blood
volume based on body weight (35ml blood per kg of mouse body
weight) (Hu et al, 2010a,b). At 90min following the injection of fVII-
SnCe6, the tumours were irradiated with 65Jcm
–2 using a 635nm
laser under anaesthesia by intraperitoneal (i.p.) injection of 100mg
ketamine per kgþ1 0 m gx y l a z i n ep e rk g .T h ed a t ef o rt h ef i r s t
treatment was designated as day 0. The fVII-tPDT treatment
procedure, that is, systemic injection of fVII-SnCe6 conjugate and
90-min post-irradiation of the tumour with 635nm laser light, was
repeated on days 6, 12, 20 and 27. The control mice were i.v. injected
with only saline buffer.
Note that we did not test the ntPDT control using unconjugated
SnCe6 in this animal study. The reason is as follows. (1) We
showed in the Results section below that the projected half-
maximal effective concentration (EC50) of laser fluence in ntPDT
using 2mM unconjugated SnCe6 was 5571.6Jcm
–2in vitro in tissue
culture plates, whereas the EC50 of laser fluence in fVII-tPDT (2mM
SnCe6 in fVII-SnCe6 conjugate) was 300-fold less (18.3Jcm
–2;
Figure 2C). Therefore, we anticipate that ntPDT at 2mM SnCe6 and
65Jcm
–2 would not have any effect on inhibiting the tumour
growth in vivo in mice. (2) We carried out four animal experiments
in our recent studies on fVII-tPDT for treatment of chemosensitive
breast cancer, and three of the ntPDTs using fVII-verteporfin or
fVII-SnCe6 conjugate were tested and compared with fVII-tPDT
and we did not observe any effect of ntPDT on inhibiting the
tumour growth (Hu et al, 2010a,b).
The efficacy of fVII-tPDT was determined by measuring tumour
width and length with calipers and calculating tumour volume
(mm
3) using the formula (width)
2 length/2 as previously
described (Hu et al, 1999; Hu and Garen, 2000, 2001). At the end
of the experiments, the mice were examined morphologically,
tumour tissues were fixed in zinc fixative (BD Biosciences),
processed, paraffin embedded, sectioned and stained by haema-
toxylin and eosin (HE) by routine methods. Tumour slides were
examined blind to experimental manipulation (by CJB). Unstained
tissue sections were used for immunohistochemistry below. Blood
samples from the mice were examined for complete blood
counting and differential analysis as additional safety assays by
Antech Diagnostics (Lake Success, NY, USA).
Immunohistochemistry (IHC) using rabbit polyclonal
antibody to murine TF for staining TF on VECs in MCF-7/
MDR tumours from mice
Based on the peptide sequence described in a previous paper
(Dackiw et al, 1996), we had Sigma-Genosis (The Woodlands, TX,
USA) produce antisera to the same 15 amino-acid residues
(CITYRKGSSTGKKTN) at the N-terminus murine TF (MTF-N)
using keyhole limpet haemocyanin-peptide to immunise New
Zealand white rabbits. The polyclonal antibody was affinity
purified from the antisera using an MTF-N peptide-coupled
Sepharose 4B column and was characterised by SDS–PAGE, dot
blotting and flow cytometry. We confirmed that it could bind to
murine TF and had crossreaction with human TF but with less
binding activity than anti-HTF antibody (HTF1) (Hu et al,
unpublished data).
Immunohistochemistry was performed as follows. MCF-7/MDR
tumour issue slides from control mice were prepared as described
above and were deparaffinised in xylene and rehydrated through
graded ethanol to distilled water and microwave-heated in an
antigen unmasking solution (Vector Laboratories) for antigen
retrieval. The sections were then incubated with 3% H2O2 for 5min
and blocked with 10% goat serum. The sections were separately
incubated with 10mgml
–1 rabbit anti-MTF-N for TF staining and
with rabbit anti-von Willebrand factor (vWF, factor VIII-related
antigen, crossreaction with human, mouse and rat origins)
(Millipore/Chemicon, Billerica, MA, USA) for endothelial staining
at 371C for 1h. Controls were incubated with isotype rabbit IgG or
with PBS buffer. Finally, the sections were incubated using
2mgml
–1 of a secondary anti-rabbit IgG alkaline phosphatase
(Vector Laboratories) for 1h at 371C. Positive blue staining for
VECs and MTF was visualised by Vector Blue substrate and cell
nuclei (red) were counterstained by Vector Nuclear Fast Red
(Vector Laboratories).
Statistical analyses
In vitro studies were carried out in duplicate wells for each group,
and in vivo efficacy in mouse tumour models were assessed in
groups of five mice per group. These data are presented as
mean±s.d. The statistical significance of differences between the
treated and control groups were analysed using paired or unpaired
t-tests or one-way ANOVA with Tukey’s multiple comparison test or
two-way ANOVA tests using Prism 5.0c (GraphPad Software, Inc.,
L aJ o l l a ,C A ,U S A ) .T h eP-values of o0.05 were considered to be
statistically significant. The half-maximal effective concentrations of
fVII-tPDT and ntPDT were calculated by the best-fit linear regression
or nonlinear one-phase decay equations using Prism 5.0c.
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TF is expressed by chemoresistant breast cancer cells and
tumour VECs in MCF-7/MDR tumours from mice
We first confirmed the expression of MDR (P-glycoprotein 170,
gp170) by the chemoresistant MCF-7/MDR breast cancer line using
western blotting with anti-gp170 antibody. Expression of gp170
was indeed detected in the cell membrane protein extracts from
MCF-7/MDR cells but not from MCF-7 cells (Figure 1A).
We next determined the expression of TF on MCF-7/MDR
cancer cells and on VECs in MCF-7/MDR tumour xenografts in
nude mice. Using flow cytometry with goat anti-human TF
antibody, we showed that MCF-7/MDR cancer cells expressed TF
with an expression level of 6.23% (Figure 1B), similar to the level
(8.16%) on the parental chemosensitive MCF-7 line (Hu et al,
2010a). Using immunohistochemical staining with a polyclonal
antibody to mouse TF (MTF), we showed that TF was expressed by
the VECs of capillary vessels with only one thin endothelial layer in
MCF-7/MDR tumours (Figure 1C, MTF, arrowheads). The
endothelial origin of these MTF-positive cells was confirmed by
positive staining for vWF (Figure 1C, vWF, arrowheads), which
labels endothelial cells as marker better than CD31 (Bairey et al,
2000). Note that isotype rabbit IgG with secondary antibody
alkaline phosphatase conjugate or secondary antibody conjugate
alone did not have any positive blue staining (not shown). Thus,
we conclude that TF is expressed on both the cancer cells and
tumour VECs in chemoresistant MCF-7/MDR breast tumours.
fVII targeting enhances the effect of SnCe6 PDT
To assess whether fVII targeting enhances the effect of SnCe6 PDT,
we compared the EC50 of SnCe6 as an indicator for the in vitro
efficacy of fVII-tPDT and ntPDT (laser fluence 18Jcm
–2)f o rM C F - 7 /
MDR cancer cells. As shown in Figure 2A, the EC50 of SnCe6 in
fVII-tPDT was 2.8mM, whereas it was 35.8mM in ntPDT (Figure 2B).
These results suggest that fVII targeting enhances the efficacy of
ntPDT for killing of MCF-7/MDR cancer cells by 12.8-fold.
To further confirm the enhanced efficacy, we treated the MCF-7/
MDR cells with fVII-tPDT and ntPDT with 2mM SnCe6 and varied
the laser fluence. We found that the effect of fVII-tPDT (2mM
SnCe6) was laser fluence dependent with an EC50 of fluence at
18.3Jcm
–2 for MCF-7/MDR cancer cells, whereas ntPDT at the
same SnCe6 concentration had no effect on killing the cancer cells
even at 43.2Jcm
–2 and its projected EC50 was 5571.6Jcm
–2
(Figure 2C), 4300-fold than that in fVII-tPDT (18.3Jcm
–2). These
results are consistent with the results in Figure 1A (i.e., the EC50 of
SnCe6 was 2.8mM when fluence was 18Jcm
–2).
From the same experiments as in Figure 2C, we photographed the
cancer cells before they were fixed for crystal violet staining. The
fVII-tPDT-treated MCF-7/MDR cancer cells became debris even by
laser fluence at 10.8Jcm
–2, and none of the cancer cells remained
intact after being treated with 43.2Jcm
–2 fVII-tPDT (data not
shown). In contrast, no cellular damage was observed in the
untreated cells or any of the ntPDT-treated cells, even by the highest
fluence (43.2Jcm
–2; data not shown). Similar observations on
cellular morphology are shown in Figure 3 below. We conclude that
fVII targeting enhances the effect of SnCe6 PDT, and fVII-tPDT is
effective in eradicating MCF-7/MDR cancer cells in vitro.
fVII-tPDT induces apoptosis and necrosis as mechanisms
of action
To understand the mechanisms of action of fVII-tPDT, we assessed
the ability of fVII-tPDT to induce apoptosis and necrosis in
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Figure 1 Tissue factor (TF) expression by chemoresistant breast cancer MCF-7/MDR cells and VECs in MCF-7/MDR tumours. (A) Multidrug resistance
(MDR; gp170) expression by western blotting. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used for comparison of protein loading.
(B) Tissue factor expression on MCF-7/MDR cancer cells was 6.23% by flow cytometry using 20mgml
–1 goat anti-HTF (blue line). The control was the
nonspecific secondary antibody FITC (red line). (C) Tissue factor expression (blue) by VECs (MTF, arrowheads) in MCF-7/MDR tumours by
immunohistochemistry using a rabbit polyclonal antibody to MTF-N. The endothelial origin of these VECs was confirmed by positively staining (blue) for the
endothelial marker vWF (vWF, arrowheads). Vector Blue chromogen and Nuclear Fast Red counterstain. Scale bar¼20mm.
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sMCF-7/MDR cancer cells 1h after treatment in vitro. Figures 3A
and B show that fVII-tPDT (2mM and 36Jcm
–2) induced
significantly higher levels of necrosis (Figure 3A) and apoptosis
(Figure 3B) than ntPDT (P¼0.0286 and Po0.0001 by one-way
ANOVA, respectively), whereas laser alone and SnCe6 alone
induced traces of necrosis, similar to that in ntPDT-treated cells
(P¼0.84 and P¼0.27 vs ntPDT by one-way ANOVA, respectively;
Figure 3A).
When visualising early necrosis and apoptosis, we observed that
all the fVII-tPDT-treated MCF-7/MDR cells were stained clearly for
obvious apoptosis (green) and necrosis (red) (Figure 3C), whereas
the ntPDT-treated and the untreated control cells were not stained
for apoptosis and necrosis (Figure 3C), consistent with the results
in Figures 3A and B. Thus, we conclude that fVII-tPDT induces
significant apoptosis and necrosis in chemoresistant breast cancer
cells immediately after the treatment when compared with ntPDT.
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Figure 2 Factor VII (fVII) targeting enhances the effect of SnCe6 PDT, and fVII-tPDT is effective in eradicating MCF-7/MDR cancer cells. (A and B) The
EC50 of SnCe6 was 2.8 and 35.8mM in fVII-tPDT and ntPDT (18Jcm
–2, laser fluence) for MCF-7/MDR cells, respectively. (C) MCF-7/MDR cells had a laser
fluence-dependent response to fVII-tPDT (2mM SnCe6) but had no response to ntPDT (2mM SnCe6).
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Figure 3 Factor VII-targeted photodynamic therapy (fVII-tPDT) induces significantly stronger levels of apoptosis and necrosis in MCF-7/MDR cancer cells
compared with ntPDT. Necrosis (cytotoxicity) (A) and apoptosis (B) were detected in fVII-tPDT (2mM SnCe6 and 36Jcm
–2)-treated MCF-7/MDR cells.
(C) Apoptosis and necrosis were visualised by immunofluorescence staining in fVII-tPDT (2mM SnCe6 and 36Jcm
–2)-treated MCF-7/MDR cells. Note that the
fVII-tPDT-treated MCF-7/MDR cells were positively stained for necrosis (red in the nuclei) and apoptosis (green), whereas the ntPDT using unconjugated
SnCe6 (2mM,3 6Jc m
–2)-treated cells and the untreated control cells did not show any staining for apoptosis and necrosis. Note that the fVII-tPDT-treated
MCF-7/MDR cells were clearly damaged, whereas the ntPDT-treated and untreated control cells were intact (phase contrast). Original magnification  400.
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sfVII-tPDT is effective and safe for treatment of
chemoresistant MCF7/MDR tumours in a nude mouse model
To assess the in vivo efficacy and safety of fVII-tPDT for
chemoresistant breast tumours, we first generated subcutaneous
MCF-7/MDR tumour xenografts in nude mice. After tumours
formed with sizes of B100–200mm
3, the mice (n¼5) were treated
by fVII-tPDT (2mM SnCe6 and 65Jcm
–2) on days 0, 6, 12, 20 and
27. The control mice (n¼5) were i.v. injected with only PBS buffer.
The tumour growth was significantly inhibited by fVII-tPDT
compared with control mice (Figure 4A; P¼0.0002 by two-tailed
t-test). The fVII-tPDT-treated tumour weights were also
significantly lighter than control tumours (Figure 4B; P¼0.0125
by two-tailed t-test).
In addition, the histopathology of stained MCF-7/MDR tumours
from control mice revealed large tumours comprising predomi-
nantly tumour cells (Figure 4A) with multiple variably sided foci of
necrosis (Figures 4C and D). In contrast, fVII-tPDT-treated
tumours were small and comprised predominantly necrotic
cellular debris (Figure 4E) with markedly fewer tumour cells and
in the process of necrosis or apoptosis as evidenced by the diffuse
nuclear pkynosis (Figure 4F), including the nuclei of large tumour
cells. The tumour cells were surrounded by necrotic cellular debris,
with frequent foci of haemosiderin-laden macrophages and
fibroblasts (Figure 4F).
Regarding the safety, we did not observe any obvious
morphological side effects in the fVII-tPDT-treated mice during
the experiments and at the time of killing the mice. In addition,
there was no statistical difference between control mice and fVII-
tPDT-treated mice in terms of complete blood count or white
blood cell differential analyses for absolute counts of neutrophils,
bands, lymphocytes, monocytes, eosinophils and basophils
(Table 1; P40.05 for fVII-tPDT vs control by two-way ANOVA
with Bonferroni post-test). Thus, we conclude that fVII-tPDT is
1000 Control
fVII-tPDT (2M, 65 J cm–2)
(P<0.0002) 800
600
T
u
m
o
u
r
 
v
o
l
u
m
e
 
(
m
m
3
)
T
u
m
o
u
r
 
w
e
i
g
h
t
 
(
g
)
400
200
0
0369 1 2 1 5 1 8 2 1
Days
24 27 30 33 36 39
0.8
0.6
0.4
0.2
0.0
Control
P=0.0125
fVII-tPDT
fVII-tPDT treated
Treatment
Control
Figure 4 Factor VII-targeted photodynamic therapy (fVII-tPDT) is effective in the treatment of chemoresistant breast cancer MCF-7/MDR tumours in
nude mice. (A and B) After fVII-tPDT treatment (2mM,6 5Jc m
–2; arrows indicating the treatment dates), MCF-7/MDR tumour volume (A) and tumour
weight (B) from fVII-tPDT-treated mice were significantly smaller than those from control mice. (C–F) Histopathology of MCF-7/MDR tumours from
control and fVII-tPDT-treated mice. MCF-7/MDR tumours from control mice (C and D) were large and had multiple variably sized foci of necrosis and
cellular debris (*) in contrast to the tumours from fVII-tPDT-treated mice (E and F) that were smaller and composed predominantly of necrotic cellular
debris (*). At increased magnification, tumour cells from MCF-7/MDR tumours (D, inset of C) were numerous, easy to identify by their dark blue
euchromatic nuclei. In contrast, distinct tumour cells from fVII-tPDT-treated (F, inset of E) mice were markedly fewer in number and in the process of
necrosis or apoptosis as evidenced by the diffuse nuclear pkynosis (arrowheads), including the nuclei of large tumour cells (double arrow). Tumour cells
were enmeshed in the background of necrotic cellular debris (*) admixed with haemosiderin-laden macrophages (m) and fibroblasts (arrows). Haematoxylin
and eosin (HE), scale bars for (C and E)¼2000mm; for (D and F)¼200mm. p¼panniculus carnosus muscle.
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seffective and safe for the treatment of chemoresistant breast cancer
in vivo in the mouse model.
DISCUSSION
Multidrug resistance is a common and major problem in the
treatment of cancer, including breast cancer (Giai et al, 1991). In
this paper we report the efficacy of fVII-tPDT using fVII-SnCe6
conjugate for the treatment of chemoresistant breast cancer by
targeting TF on chemoresistant breast cancer cells and tumour
VECs. In this study we show that fVII-tPDT eradicates chemo-
resistant breast cancer cells in vitro and significantly inhibits the
tumour growth in vivo in a nude mouse model of chemoresistant
breast cancer. To our knowledge, this is the first presentation of a
novel, effective and dual neovascular- and cancer cell-targeting
fVII-tPDT as an alternative to chemotherapy to bypass drug
resistance of cancer.
Photodynamic therapy has several important advantages
compared with chemotherapy. First, several studies have reported
that MDR tumour lines were equally sensitive to PDT when
compared with the chemosensitive parental lines (Kessel and
Erickson, 1992; Kusuzaki et al, 2000). Second, the PDT procedure
can be repeated multiple times if needed because there are no
cumulative toxic effects and it is usually an outpatient procedure
(Capella and Capella, 2003). Third, it can be used as a stand-alone
modality or in combination with other therapies, including
antiangiogenesis, surgery, radiotherapy and other treatments.
As discussed above, the main limitation of ntPDT is sensitisa-
tion to sunlight, such that patients undergoing PDT have to avoid
direct sunlight and bright indoor light for a few days to weeks. To
overcome the poor selectivity of PS, oestrogen receptors, epithelial
growth receptors and HER-2 antigens expressed by breast cancer
cells have been targeted by ligands or antibody/antibody fragments
for the development of tPDT (Gijsens et al, 2000; Swamy et al,
2002, 2006; Savellano et al, 2005; Bhatti et al, 2008). In this regard,
we were able to simultaneously target angiogenic VECs and cancer
cells by targeting receptor TF using its natural ligand fVII-
conjugated SnCe6 or verteporfin for the treatment of breast cancer
in preclinical studies (Hu et al, 2010a,b).
The reason for targeting TF by fVII was that TF is selectively
expressed by angiogenic VECs and overexpressed by many types
of cancer cells (Contrino et al, 1996; Hu et al, 1999; Hu and Garen,
2001; Tang et al, 2007). Moreover, fVII binds to TF with high
affinity and specificity (Waxman et al, 1992). In the course of the
development of the TF-targeting concept and therapeutic agents
using fVII, Hu and Garen (2000, 2001) constructed the first
TF-targeting agent, an fVII/IgG1 Fc immunoconjugate (called an
Icon) for immunotherapy of cancer (Hu et al, 1999). Given that TF
was detected on angiogenic VECs in cancer (Contrino et al, 1996;
Hu et al, 1999; Hu and Garen, 2001; Tang et al, 2007; Cocco et al,
2010) and other pathological neovasculature-involved diseases
such as wMD (Bora et al, 2003; Tezel et al, 2007) and
endometriosis (Krikun et al, 2010), Icon immunotherapy was
effective and safe for the treatment of cancer (Hu et al, 1999;
Hu and Garen, 2000, 2001; Tang et al, 2007; Cocco et al, 2010),
wMD (Bora et al, 2003; Tezel et al, 2007) and endometriosis
(Krikun et al, 2010) in preclinical studies. In 2008, Shoji et al
(2008) reported the use of an active site-inactivated recombinant
human fVIIa (FFRck–fVIIa) as a carrier for the targeted delivery
of a potent synthetic curcumin analogue (EF24) to TF-expressing
tumour-associated VECs and tumours.
Here, we report a different TF-targeting therapeutics using fVII-
conjugated photoactivatable SnCe6 for the treatment of chemo-
resistant human breast tumour. Contrino et al (1996) showed that
TF was expressed on VECs of breast cancer cells but not on normal
VECs of the breast from human subjects. We previously showed
that mouse Icon (murine fVII/hIgG1 Fc) protein could selectively
bind to tumour VECs in human melanoma and prostatic tumour
xenografts but to VECs in several normal organs from severe
combined immunodeficient mice (see Figure 3 in Hu et al, 1999
and Figure 7 in Hu and Garen, 2001, respectively), suggesting that
TF is also selectively expressed by tumour VECs in human tumour
xenografts but not by normal VECs from mice. However, it was
previously unknown whether TF is expressed on VECs in
chemoresistant breast tumours. Here, we showed for the first time
that TF was indeed expressed on tumour VECs in chemoresistant
MCF-7/MDR breast tumours. These results provide the basis and
rationale for the efficacy of fVII-tPDT via targeting TF for the
treatment of chemoresistant breast tumours. We then showed that
fVII-tPDT induced both apoptosis and necrosis, as a mechanism of
action, in MCF-7/MDR cancer cells and that fVII-tPDT was
effective in eradicating MCF-7/MDR cancer cells in vitro and
inhibiting tumour growth in vivo. Thus, fVII-tPDT as a localised
therapy is different in the mechanism of action from Icon
immunotherapy, which is a systemic modality and relies on host
immune functions through NK cell- and complement-mediated
cytotoxicity (Hu and Li, 2010). Taking the results together, we
Table 1 CBC with WBC differential in the control and fVII-tPDT-treated mice
CBC/differential Control (n¼5) fVII-tPDT (n¼5) P-value Reference range
Haemoglobin (gdl
–1) 14.2±0.2 13.6±1.0 40.05 13.0–15.0
Haematocrit (%) 45.3±2.0 42.6±3.3 40.05 33.0–50.0
WBC (10
3ml
–1) 5.0±2.1 5.3±2.7 40.05 5.0–10.0
RBC (10
6ml
–1) 9.4±0.2 8.7±0.9 40.05 5.5–10.5
MCV (fl) 48.4±1.8 49.6±5.2 40.05 NA
MCH (pg) 15.2±0.3 15.7±1.5 40.05 NA
MCHC (gdl
–1) 31.5±1.2 31.9±1.0 40.05 NA
Platelet count (10
3ml
–1) 837.2±116.6 948.6±610.5 40.05 NA
Neutrophils 1261.6±916.3 1788.0±1974.7 40.05 NA
Neutrophilic bands 0.0±0.0 0.0±0.0 40.05 NA
Lymphocytes 3581.6±1165.5 3373.2±718.0 40.05 NA
Monocytes 60.4±30.7 54.6±83.4 40.05 NA
Eosinophils 86.0±40.9 88.2±64.9 40.05 NA
Basophils 50.4±21.2 16.0±22.8 40.05 NA
Abbreviations: CBC¼complete blood count; WBC¼white blood cells; RBC¼red blood cells; MCV¼mean corpuscular volume (the average volume of the red cells,
measured in femtolitres); MCH¼mean corpuscular haemoglobin (the average amount of haemoglobin per red blood cell, in pg); MCHC¼mean corpuscular haemoglobin
concentration (the average concentration of haemoglobin in the cells); NA¼not available from Antech Diagnostics Inc.; fVII-tPDT¼factor VII-targeted photodynamic therapy.
P-values were analysed by two-way ANOVA using Prism 5.0c.
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potentially in combination with Icon immunotherapy for the
treatment of chemoresistant cancer.
In conclusion, we report here an effective and safe fVII-tPDT for
the treatment of chemoresistant breast cancer by selectively
targeting tumour VECs and the cancer cells. This TF-targeting
fVII-tPDT could have therapeutic potential for the treatment of
other chemoresistant cancers, as all tumours, including chemo-
resistant tumours and leukaemia, do need and have neovasculature
(Bairey et al, 2000; Michaelis et al, 2009), in which TF is expressed
by tumour VECs and/or cancer cells (Andoh et al, 1987; Bauer
et al, 1989; Callander et al, 1992; Hair et al, 1996; Shoji et al, 1998;
Hu et al, 1999; Hu and Garen, 2000, 2001).
ACKNOWLEDGEMENTS
We thank Dr Zping Lin and Dr Alan Clayton Sartorelli at Yale
University for providing MCF-7 and MCF-7/MDR cancer lines and
Gordon Terwilliger at Yale Section of Comparative Medicine for
examining the mice at the time of sacrifice of the animals. This
work was supported by the Breast Cancer Alliance (Exceptional
Project Grant) (to ZH), and partly by the Komen Award
(BCTR0601204) from the Susan G Komen for the Cure Foundation
(to ZH), the CT DPH Biomedical Research Grant (RFP no. 2009-
0096) (to ZH) and the NIH Research Grant CA-16359 from the
National Cancer Institute for the use of Yale Cancer Center’s
shared facilities.
Conflict of interest
The authors declare no conflict of interest. Author information
Present address for JC: The First-affiliated Hospital of Nanchang
University, Jiangxi, China.
Author contributions
ZH designed the research, wrote the paper, constructed plasmid
vectors and CHO producer lines, produced polyclonal antibody to
MTF-N and established the key procedures for conjugation and
fVII-tPDT in vitro and in vivo. JD carried out most of the in vitro
and in vivo experiments. JC carried out immunofluorescence
staining for apoptosis/necrosis, JX carried out IHC staining and
CJB summarised the IHC results. All authors read and approved
the final manuscript.
REFERENCES
Alessi P, Ebbinghaus C, Neri D (2004) Molecular targeting of angiogenesis.
Biochim Biophys Acta 1654(1): 39–49
Andoh K, Kubota T, Takada M, Tanaka H, Kobayashi N, Maekawa T (1987)
Tissue factor activity in leukemia cells. Special reference to disseminated
intravascular coagulation. Cancer 59(4): 748–754
Bairey O, Zimra Y, Kaganovsky E, Shaklai M, Okon E, Rabizadeh E (2000)
Microvessel density in chemosensitive and chemoresistant diffuse large
B-cell lymphomas. Med Oncol 17(4): 314–318
Bauer KA, Conway EM, Bach R, Konigsberg WH, Griffin JD, Demetri G
(1989) Tissue factor gene expression in acute myeloblastic leukemia.
Thromb Res 56(3): 425–430
Bhatti M, Yahioglu G, Milgrom LR, Garcia-Maya M, Chester KA, Deonarain MP
(2008) Targeted photodynamic therapy with multiply-loaded recombi-
nant antibody fragments. Int J Cancer 122(5): 1155–1163
Bora PS, Hu Z, Tezel TH, Sohn JH, Kang SG, Cruz JM, Bora NS, Garen A,
Kaplan HJ (2003) Immunotherapy for choroidal neovascularization in a
laser-induced mouse model simulating exudative (wet) macular degen-
eration. Proc Natl Acad Sci USA 100(5): 2679–2684
Callander NS, Varki N, Rao LV (1992) Immunohistochemical identification
of tissue factor in solid tumors. Cancer 70(5): 1194–1201
Capella MA, Capella LS (2003) A light in multidrug resistance:
photodynamic treatment of multidrug-resistant tumors. J Biomed Sci
10(4): 361–366
Cocco E, Hu Z, Richter CE, Bellone S, Casagrande F, Bellone M,
Todeschini P, Krikun G, Silasi DA, Azodi M, Schwartz PE, Rutherford
TJ, Buza N, Pecorelli S, Lockwood CJ, Santin AD (2010) hI-con1, a
factor VII-IgGFc chimeric protein targeting tissue factor for immuno-
therapy of uterine serous papillary carcinoma. Br J Cancer 103(6):
812–819
Contrino J, Hair G, Kreutzer DL, Rickles FR (1996) In situ detection of
tissue factor in vascular endothelial cells: correlation with the malignant
phenotype of human breast disease. Nat Med 2(2): 209–215
D a c k i wA P ,M c G i l v r a yI D ,W o o d s i d eM ,N a t h e n sA B ,M a r s h a l lJ C ,R o t s t e i nO D
(1996) Prevention of endotoxin-induced mortality by antitissue factor
immunization. Arch Surg 131(12): 1273–1278; discussion 1278–1279
Drake TA, Morrissey JH, Edgington TS (1989) Selective cellular expression
of tissue factor in human tissues. Implications for disorders of
hemostasis and thrombosis. Am J Pathol 134(5): 1087–1097
Fernandez PM, Rickles FR (2002) Tissue factor and angiogenesis in cancer.
Curr Opin Hematol 9(5): 401–406
Flossel C, Luther T, Muller M, Albrecht S, Kasper M (1994) Immunohis-
tochemical detection of tissue factor (TF) on paraffin sections of
routinely fixed human tissue. Histochemistry 101(6): 449–453
Forster Y, Meye A, Albrecht S, Schwenzer B (2006) Tissue factor and tumor:
clinical and laboratory aspects. Clin Chim Acta 364(1-2): 12–21
Giai M, Biglia N, Sismondi P (1991) Chemoresistance in breast tumors. Eur
J Gynaecol Oncol 12(5): 359–373
Gijsens A, Missiaen L, Merlevede W, de Witte P (2000) Epidermal growth
factor-mediated targeting of chlorin e6 selectively potentiates its
photodynamic activity. Cancer Res 60(8): 2197–2202
Hair GA, Padula S, Zeff R, Schmeizl M, Contrino J, Kreutzer DL, de
Moerloose P, Boyd AW, Stanley I, Burgess AW, Rickles FR (1996) Tissue
factor expression in human leukemic cells. Leuk Res 20(1): 1–11
Hu Z, Garen A (2000) Intratumoral injection of adenoviral vectors
encoding tumor-targeted immunoconjugates for cancer immunotherapy.
Proc Natl Acad Sci USA 97(16): 9221–9225
Hu Z, Garen A (2001) Targeting tissue factor on tumor vascular endothelial
cells and tumor cells for immunotherapy in mouse models of prostatic
cancer. Proc Natl Acad Sci USA 98(21): 12180–12185
Hu Z, Li J (2010) Natural killer cells are crucial for the efficacy of Icon
(factor VII/human IgG1 Fc) immunotherapy in human tongue cancer.
BMC Immunol 11: 49
Hu Z, Rao B, Chen S, Duanmu J (2010a) Selective and effective killing of
angiogenic vascular endothelial cells and cancer cells by targeting tissue
factor using a factor VII-targeted photodynamic therapy for breast
cancer. Breast Cancer Res Treat 126(3): 589–600
Hu Z, Rao B, Chen S, Duanmu J (2010b) Targeting tissue factor on tumour
cells and angiogenic vascular endothelial cells by factor VII-targeted
verteporfin photodynamic therapy for breast cancer in vitro and in vivo
in mice. BMC Cancer 10: 235
Hu Z, Sun Y, Garen A (1999) Targeting tumor vasculature endothelial cells
and tumor cells for immunotherapy of human melanoma in a mouse
xenograft model. Proc Natl Acad Sci USA 96(14): 8161–8166
Kessel D, Erickson C (1992) Porphyrin photosensitization of multi-drug
resistant cell types. Photochem Photobiol 55(3): 397–399
Kim JS, Raines RT (1993) Ribonuclease S-peptide as a carrier in fusion
proteins. Protein Sci 2(3): 348–356
Kiss Z, Tomono M, Anderson WB (1994) Phorbol ester selectively
stimulates the phospholipase D-mediated hydrolysis of phosphatidy-
lethanolamine in multidrug-resistant MCF-7 human breast carcinoma
cells. Biochem J 302(Part 3): 649–654
Krikun G, Hu Z, Osteen K, Bruner-Tran KL, Schatz F, Taylor HS, Toti P,
Arcuri F, Konigsberg W, Garen A, Booth CJ, Lockwood CJ (2010)
The immunoconjugate ‘icon’ targets aberrantly expressed endothelial
tissue factor causing regression of endometriosis. Am J Pathol 176(2):
1050–1056
Kusuzaki K, Minami G, Takeshita H, Murata H, Hashiguchi S, Nozaki T,
Ashihara T, Hirasawa Y (2000) Photodynamic inactivation with acridine
orange on a multidrug-resistant mouse osteosarcoma cell line. Jpn J
Cancer Res 91(4): 439–445
Treatment of chemoresistant breast cancer by fVII-tPDT
J Duanmu et al
1408
British Journal of Cancer (2011) 104(9), 1401–1409 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sMayo GL, Melendez RF, Kumar N, McKinnon SJ, Glickman RD (2003)
Antibody-targeted photodynamic therapy. Am J Ophthalmol 136(6):
1151–1152
Merlin JL, Gautier H, Barberi-Heyob M, Teiten MH, Guillemin F (2003) The
multidrug resistance modulator SDZ-PSC 833 potentiates the photo-
dynamic activity of chlorin e6 independently of P-glycoprotein in
multidrug resistant human breast adenocarcinoma cells. Int J Oncol
22(4): 733–739
Michaelis M, Klassert D, Barth S, Suhan T, Breitling R, Mayer B, Hinsch N,
Doerr HW, Cinatl J, Cinatl Jr J (2009) Chemoresistance acquisition induces
a global shift of expression of aniogenesis-associated genes and increased
pro-angogenic activity in neuroblastoma cells. Mol Cancer 8: 80
Mickuviene I, Kirveliene V, Juodka B (2004) Experimental survey of non-
clonogenic viability assays for adherent cells in vitro. Toxicol In Vitro
18(5): 639–648
Milsom C, Anderson GM, Weitz JI, Rak J (2007) Elevated tissue factor
procoagulant activity in CD133-positive cancer cells. J Thromb Haemost
5(12): 2550–2552
Savellano MD, Pogue BW, Hoopes PJ, Vitetta ES, Paulsen KD (2005)
Multiepitope HER2 targeting enhances photoimmunotherapy of HER2-
overexpressing cancer cells with pyropheophorbide-a immunoconju-
gates. Cancer Res 65(14): 6371–6379
Sharman WM, van Lier JE, Allen CM (2004) Targeted photodynamic
therapy via receptor mediated delivery systems. Adv Drug Deliv Rev
56(1): 53–76
Shoji M, Hancock WW, Abe K, Micko C, Casper KA, Baine RM, Wilcox JN,
Danave I, Dillehay DL, Matthews E, Contrino J, Morrissey JH, Gordon S,
Edgington TS, Kudryk B, Kreutzer DL, Rickles FR (1998) Activation of
coagulation and angiogenesis in cancer: immunohistochemical localiza-
tion in situ of clotting proteins and vascular endothelial growth factor in
human cancer. Am J Pathol 152(2): 399–411
Shoji M, Sun A, Kisiel W, Lu YJ, Shim H, McCarey BE, Nichols C, Parker
ET, Pohl J, Mosley CA, Alizadeh AR, Liotta DC, Snyder JP (2008)
Targeting tissue factor-expressing tumor angiogenesis and tumors with
EF24 conjugated to factor VIIa. J Drug Target 16(3): 185–197
Swamy N, James DA, Mohr SC, Hanson RN, Ray R (2002) An estradiol-
porphyrin conjugate selectively localizes into estrogen receptor-positive
breast cancer cells. Bioorg Med Chem 10(10): 3237–3243
Swamy N, Purohit A, Fernandez-Gacio A, Jones GB, Ray R (2006) Nuclear
estrogen receptor targeted photodynamic therapy: selective uptake and
killing of MCF-7 breast cancer cells by a C17alpha-alkynylestradiol-
porphyrin conjugate. J Cell Biochem 99(3): 966–977
Tang Y, Borgstrom P, Maynard J, Koziol J, Hu Z, Garen A, Deisseroth A
(2007) Mapping of angiogenic markers for targeting of vectors to tumor
vascular endothelial cells. Cancer Gene Therapy 14(4): 346–353
Tezel TH, Bodek E, Sonmez K, Kaliappan S, Kaplan HJ, Hu Z, Garen A
(2007) Targeting tissue factor for immunotherapy of choroidal
neovascularization by intravitreal delivery of factor VII-Fc chimeric
antibody. Ocul Immunol Inflamm 15(1): 3–10
Waxman E, Ross JB, Laue TM, Guha A, Thiruvikraman SV, Lin TC,
Konigsberg WH, Nemerson Y (1992) Tissue factor and its extracellular
soluble domain: the relationship between intermolecular association with
factor VIIa and enzymatic activity of the complex. Biochemistry 31(16):
3998–4003
Treatment of chemoresistant breast cancer by fVII-tPDT
J Duanmu et al
1409
British Journal of Cancer (2011) 104(9), 1401–1409 & 2011 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s